Total Payments
$290,400
2024 Payments
$53,987
Companies
39
Transactions
929
Medicare Patients
9,703
Medicare Billing
$535,158
Payment Breakdown by Category
Other$246,429 (84.9%)
Food & Beverage$21,417 (7.4%)
Consulting$16,144 (5.6%)
Travel$6,071 (2.1%)
Education$339.85 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $214,789 | 101 | 74.0% |
| Honoraria | $31,640 | 10 | 10.9% |
| Food and Beverage | $21,417 | 766 | 7.4% |
| Consulting Fee | $16,144 | 11 | 5.6% |
| Travel and Lodging | $6,071 | 30 | 2.1% |
| Education | $339.85 | 11 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $69,776 | 114 | $0 (2024) |
| Lilly USA, LLC | $32,581 | 41 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $31,983 | 31 | $0 (2024) |
| Merck Sharp & Dohme LLC | $28,125 | 56 | $0 (2024) |
| Esperion Therapeutics, Inc. | $26,689 | 33 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $26,111 | 47 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $24,539 | 112 | $0 (2024) |
| PFIZER INC. | $23,058 | 51 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,921 | 59 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $7,380 | 119 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,987 | 141 | Lexicon Pharmaceuticals, Inc. ($19,708) |
| 2023 | $57,717 | 154 | Merck Sharp & Dohme LLC ($13,585) |
| 2022 | $48,065 | 154 | Merck Sharp & Dohme LLC ($14,370) |
| 2021 | $49,259 | 153 | Esperion Therapeutics, Inc. ($16,792) |
| 2020 | $33,040 | 121 | Esperion Therapeutics, Inc. ($9,858) |
| 2019 | $25,580 | 124 | Lilly USA, LLC ($13,537) |
| 2018 | $22,558 | 73 | Boehringer Ingelheim Pharmaceuticals, Inc. ($17,641) |
| 2017 | $192.06 | 9 | E.R. Squibb & Sons, L.L.C. ($106.33) |
All Payment Transactions
929 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: Cardio-renal | ||||||
| 12/13/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/03/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Cardiology | ||||||
| 11/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,716.00 | General |
| Category: Cardio-renal | ||||||
| 11/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: DIABETES | ||||||
| 10/25/2024 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: WATCHMAN_IC | ||||||
| 10/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: DIABETES | ||||||
| 10/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 10/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Cardiology | ||||||
| 10/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Honoraria | Cash or cash equivalent | $1,870.00 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Diabetes | ||||||
| 10/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $4.37 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/09/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: Genetic Disease | ||||||
| 10/08/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Honoraria | Cash or cash equivalent | $1,250.00 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 10/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $8.95 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,584 | 2,974 | $399,909 | $123,865 |
| 2022 | 21 | 2,722 | 3,231 | $437,697 | $148,841 |
| 2021 | 21 | 2,260 | 2,857 | $414,596 | $142,412 |
| 2020 | 21 | 2,137 | 2,584 | $361,780 | $120,041 |
Total Patients
9,703
Total Services
11,646
Medicare Billing
$535,158
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 383 | 565 | $132,775 | $45,502 | 34.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 186 | 193 | $87,043 | $24,996 | 28.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 286 | 286 | $40,612 | $13,512 | 33.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 69 | $16,008 | $6,141 | 38.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 50 | $15,850 | $6,081 | 38.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 732 | 851 | $21,275 | $5,361 | 25.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $11,552 | $3,339 | 28.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 56 | $9,016 | $3,325 | 36.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 274 | 295 | $16,520 | $2,812 | 17.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 47 | 47 | $8,319 | $2,428 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $6,810 | $2,226 | 32.7% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 90 | 98 | $5,684 | $1,660 | 29.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $4,880 | $1,403 | 28.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 87 | 87 | $4,872 | $1,289 | 26.5% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2023 | 11 | 11 | $7,788 | $962.06 | 12.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 20 | 20 | $2,840 | $888.59 | 31.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 87 | 87 | $3,132 | $859.19 | 27.4% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 61 | 63 | $1,008 | $328.80 | 32.6% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 78 | 82 | $738.00 | $177.84 | 24.1% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 12 | 12 | $672.00 | $177.21 | 26.4% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Facility | 2023 | 11 | 11 | $737.00 | $140.30 | 19.0% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 13 | 16 | $1,346 | $133.20 | 9.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 12 | 12 | $432.00 | $121.52 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 402 | 643 | $151,105 | $55,996 | 37.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 343 | 346 | $49,132 | $17,917 | 36.5% |
About Dr. Kamal Shemisa, MD
Dr. Kamal Shemisa, MD is a Cardiovascular Disease healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2009. The National Provider Identifier (NPI) number assigned to this provider is 1326281007.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kamal Shemisa, MD has received a total of $290,400 in payments from pharmaceutical and medical device companies, with $53,987 received in 2024. These payments were reported across 929 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($214,789).
As a Medicare-enrolled provider, Shemisa has provided services to 9,703 Medicare beneficiaries, totaling 11,646 services with total Medicare billing of $535,158. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Cincinnati, OH
- Active Since 04/11/2009
- Last Updated 07/21/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1326281007
Products in Payments
- JARDIANCE (Drug) $100,788
- Inpefa (Drug) $31,872
- VERQUVO (Drug) $28,125
- NEXLIZET (Drug) $24,711
- XARELTO (Drug) $24,451
- Kerendia (Drug) $23,922
- VYNDAQEL (Drug) $19,402
- FARXIGA (Drug) $6,914
- LEQVIO (Drug) $6,208
- Vascepa (Drug) $5,330
- LifeVest (Device) $2,211
- NEXLETOL (Drug) $1,978
- MOUNJARO (Drug) $1,193
- ENTRESTO (Drug) $1,133
- Repatha (Biological) $872.67
- Ozempic (Drug) $590.65
- BRILINTA (Drug) $588.00
- ELIQUIS (Drug) $419.39
- EVKEEZA (Biological) $249.65
- WATCHMAN Access System (Device) $215.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Cincinnati
Timothy Henry, Md, MD
Cardiovascular Disease — Payments: $731,232
Cardiovascular Disease $731,232
Eugene Chung, M.d, M.D
Cardiovascular Disease — Payments: $471,614
Cardiovascular Disease $471,614
Eli Roth, Md, MD
Cardiovascular Disease — Payments: $371,143
Cardiovascular Disease $371,143
Santiago Garcia, Md, MD
Cardiovascular Disease — Payments: $308,252
Cardiovascular Disease $308,252
Joseph Choo, M.d, M.D
Cardiovascular Disease — Payments: $274,686
Cardiovascular Disease $274,686
John Corl, Md, MD
Cardiovascular Disease — Payments: $268,780
Cardiovascular Disease $268,780